PeptideGlobal

Ribupatide weight loss trial in China puts Hengrui obesity filing in focus

A Phase 3 study published in JAMA found weight fell up to 17.7% over 48 weeks on Jiangsu Hengrui's weekly ribupatide in Chinese adults without diabetes. China's regulator is reviewing the drug, and no head to head data exist.

Illustration for the story: Ribupatide weight loss trial in China puts Hengrui obesity filing in focus

Illustration by Peptide Global, not a picture of the place in the story.

The short of itA Phase 3 trial in 567 Chinese adults without diabetes found weekly ribupatide cut body weight by up to 17.7% at 48 weeks, against 1.4% on placebo.

A Phase 3 ribupatide weight loss trial in China has found that adults without diabetes lost up to 17.7% of their body weight over 48 weeks on the highest of three dose levels. The GEMINI-1 study, sponsored by Jiangsu Hengrui Pharmaceuticals, was published online in JAMA on 15 November. It arrives while China's drug regulator reviews a marketing application for the weekly injection, which acts on both the GIP and GLP-1 receptors. The study compared ribupatide with placebo only, not with any approved drug.

What the GEMINI 1 study tested

The trial enrolled 567 adults at 55 hospitals and clinics in China between May and June 2024, according to the JAMA research summary by Lin Zhao, Ying Chen, Zhifeng Cheng and colleagues. To qualify, people needed a body mass index of at least 28, or at least 24 with one weight related condition, and they could not have diabetes. Participants were randomly assigned to one of three ribupatide dose levels or to placebo, and everyone received lifestyle counselling. Doses started low and rose in steps every four weeks until each group reached its target. The group was young for an obesity study, with a mean age of about 34, and slightly more than half were women. Mean starting weight was 93.0 kg.

Ribupatide is a weekly injection that activates two gut hormone receptors, GIP and GLP-1, the same pairing used by tirzepatide. Hengrui developed it under the code HRS9531, and the study is registered as NCT06396429. Outside Greater China the rights sit with Kailera Therapeutics, which tests the drug as KAI-9531 in its own global Phase 3 programme. The main measure of the ribupatide weight loss trial was the change in body weight after 48 weeks. Chinese doctors already have several weekly options, including semaglutide, tirzepatide and the domestic drugs mazdutide and ecnoglutide, which join the national insurance list for diabetes from January. Ribupatide would enter a crowded and fast moving home market.

Weight results by dose

Mean body weight fell 10.7% in the lowest dose group, 16.4% in the middle group and 17.7% in the highest group, against 1.4% on placebo. The differences from placebo were 9.3, 15.0 and 16.3 percentage points, all statistically significant. About 68% of the low dose group, 88% of the middle group and 86% of the high dose group lost at least 5% of their weight, compared with 16% on placebo. At the 20% mark, 37.1% of the middle group and 44.4% of the high dose group reached it. The authors wrote that weight curves in the two higher groups had not clearly flattened by week 48, so the full effect may be larger.

The differences from placebo were 9.3, 15.0 and 16.3 percentage points, all statistically significant.

Those figures invite comparison with other drugs, but the authors warned that numbers from separate trials can only be set side by side descriptively. They cited SURMOUNT-CN, a Chinese study of tirzepatide, in which the top dose produced about 17.5% weight loss at 52 weeks. Popular coverage, including a report by UNILAD, set ribupatide against Wegovy and Mounjaro results from longer global trials that used different people and durations. The fair reading is narrower. In young Chinese adults without diabetes, ribupatide produced large weight loss against placebo within 48 weeks, and the higher doses had not reached their ceiling. Only a head to head trial could show whether it beats an approved drug.

ItemDetail
TrialGEMINI-1, Phase 3, NCT06396429
SponsorJiangsu Hengrui Pharmaceuticals
Sites55 in China
Participants567 adults with overweight or obesity, no diabetes
Length48 weeks with lifestyle counselling
Weight change, low, middle and high dose10.7%, 16.4% and 17.7%
Weight change, placebo1.4%
Gut side effects47.9% to 63.1% on ribupatide, 23.1% on placebo
PublishedJAMA, online 15 November 2026
China filingAccepted by NMPA in November 2025, no decision yet

Safety signals and limits

Stomach and gut complaints were the most common side effects, as with other drugs of this class. Gastrointestinal adverse events affected 47.9%, 58.2% and 63.1% of people in the three ribupatide groups, against 23.1% on placebo. Most were diarrhoea, nausea or vomiting, mostly mild or moderate, and they clustered in the weeks when doses were being raised. Only one or two people per ribupatide group stopped treatment because of side effects, and nobody on placebo did. Serious adverse events ran from 1.4% to 5.0% across the ribupatide groups and 5.6% on placebo. There were no cases of medullary thyroid cancer or acute pancreatitis, according to a summary of the paper by AJMC.

Three people taking ribupatide were diagnosed with papillary thyroid cancer during the study, which investigators judged probably unrelated to treatment. Regulators will still look at that finding, because thyroid tumours are a standing question for drugs that act on the GLP-1 receptor. The authors also listed limits of their own. The 48 week period may have ended before the full effect of the two higher doses, and the participants were relatively young, so the efficacy and safety results may not carry over to older adults with obesity. Secondary results on waist size, blood pressure and blood sugar were not adjusted for multiple testing, which means they support the main finding but cannot stand on their own as proof.

What the result means for China

For Hengrui the ribupatide weight loss trial is the main evidence behind its home filing. China's National Medical Products Administration accepted a marketing application for ribupatide in chronic weight management in November 2025, AJMC reported, and no decision has been announced. If approved, it would join several domestic drugs built on GLP-1 biology. Copies of semaglutide are also on the way, with filings such as the United Laboratories semaglutide application for weight management already under review. Price will matter as much as efficacy, because the national insurance list pays for these drugs in type 2 diabetes, not for weight loss alone, so most obesity patients would pay themselves.

Outside China the results feed into Kailera's plans. The company is running global Phase 3 trials of KAI-9531 that test higher maintenance doses than GEMINI-1 used, and a separate cardiovascular outcomes trial in people with atherosclerotic heart disease is under way, according to AJMC. Those studies, not the Chinese data alone, will decide approvals in the United States or Europe. The secondary gains also matter for doctors. Against placebo, waist size fell by 6.4 to 11.8 cm and systolic blood pressure by 7.1 to 8.7 mm Hg. Both point to the cardiometabolic benefit the authors say is being studied further, and they will shape how Chinese doctors weigh ribupatide against existing options once a decision arrives.

Conclusion

The ribupatide weight loss trial gives Hengrui a strong placebo controlled result in Chinese adults without diabetes, with up to 17.7% weight loss at 48 weeks and gut side effects as the main cost. It is not a head to head win over Wegovy or Mounjaro. The next markers are the NMPA decision on the weekly injection, Kailera's global Phase 3 readouts and longer follow up on the thyroid findings.

Why it matters in China

Hengrui has a weight management application for ribupatide under review at China's NMPA, and the drug would enter a home market already crowded with semaglutide, tirzepatide, mazdutide and ecnoglutide, where obesity use is not reimbursed.

What to watch

The NMPA decision on Hengrui's application, Kailera's global Phase 3 results for KAI-9531 and longer follow up on the three papillary thyroid cancer cases.

Sources

  1. JAMA: Once-Weekly Ribupatide for Weight Loss in Adults in China With Overweight or Obesity, Research Summary
  2. AJMC: Ribupatide Yields Up to 17.7% Weight Loss in Phase 3 GEMINI-1 Trial
  3. UNILAD: New Chinese weight loss jab could rival the top GLP-1s

Spotted a wrong figure? Tell the desk; we fix errors under our corrections policy.

Peptide Global reports news about medicines and markets. Nothing here is medical or investment advice.